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Stress-related behavior in Brattleboro rat after DDAVP treatment 
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 The effect of AVP on affective and memory symptoms is due to its central role 
 DDAVP treatment compensated the peripheral effects of congenital AVP absence 
 DDAVP did not significantly alter the behavior of KO animals in the paradigms tested 





Beside its hormonal function in salt and water homeostasis, vasopressin – released into distinct 
brain areas – plays a crucial role in stress-related behavior resulting in the enhancement of an 
anxious/depressive-like state.  
We aimed to investigate whether correction of the peripheral symptoms of congenital absence of 
AVP also corrects the behavioral alterations in AVP-deficient Brattleboro rats. Wild type (WT) and 
vasopressin-deficient (KO) male Brattleboro rats were tested.  
Half of the KO animals were treated by desmopressin (V2-receptor agonist) via osmotic minipump 
(subcutaneous) to eliminate the peripheral symptoms of vasopressin-deficiency. Anxiety was studied 
by elevated plus maze (EPM), defensive withdrawal (DW) and marble burying (MB) tests, while 
depressive-like changes were monitored in forced swimming (FS) and anhedonia by sucrose 
preference test. Cell activity was examined in septum and amygdala by c-Fos immunohistochemistry 
after 10min FS. 
KO rats spent more time in the open arm of the EPM, spent less time at the periphery of DW and 
showed less burying behavior in MB suggesting a reduced anxiety state. KO animals showed less 
floating behavior during FS revealing a less depressive phenotype. Desmopressin treatment 
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compensated the peripheral effects of vasopressin-deficiency without a significant influence on the 
behavior. The FS-induced c-Fos immunoreactivity in the medial amygdala was different in WT and 
KO rats, with almost identical levels in KO and desmopressin treated animals. There were no 
differences in central and basolateral amygdala as well as in lateral septum.  
Our data confirmed the role of vasopressin in the development of affective disorders through central 
mechanisms. The involvement of the medial amygdala in the behavioral alterations of vasopressin 
deficient animals deserves further attention. 
Keywords: DDAVP, anxiety, depression, recognition memory, amygdala, lateral septum 
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Stress is defined as an adaptive reaction to disturbed homeostasis due to internal or external 
hazards (Holsboer and Ising, 2010). Prolonged and repeated exposures to unavoidable, aversive 
stimuli may lead to a dysregulation of the hypothalamic-pituitary-adrenocortical (HPA) axis, the 
major endocrine component of the stress response. A maladaptive stress response is thought to be 
causally linked to a variety of human disorders including mood disorders (Chrousos and Gold, 1992, 
Chrousos, 1998, Holsboer, 2000, McEwen, 2000, Engelmann et al., 2004). The physiological 
foundation of the HPA axis is constituted by parvocellular neurons of the hypothalamic 
paraventricular nucleus (PVN). These neurons secrete the corticotropin-releasing hormone (CRH) 
into the portal blood vessels to trigger adrenocorticotropin (ACTH) release from the anterior 
pituitary (Antoni, 1993). ACTH reaches the adrenal gland through the systemic circulation to 
stimulate the synthesis and release of glucocorticoids. In addition to CRH, parvocellular cells can also 
synthesize and release arginine-vasopressin (AVP). AVP is also capable of triggering ACTH release 
after interaction with V1b receptors in the anterior pituitary, potentiating the effect of CRH (Antoni, 
1993, Holmes et al., 2003). 
Originally, the endocrine function of AVP was primarily linked to the salt and water 
homeostasis in mammals. The hypothalamic-neurohypophyseal system (HNS) (Cunningham and 
Sawchenko, 1991, Johnson et al., 1993, Kato et al., 1995) is constituted by magnocellular neurons 
located in the PVN and hypothalamic supraoptic nucleus (SON) sending their axons to the posterior 
pituitary, where AVP is released into the general circulation to control antidiuresis and 
vasoconstriction/glycogen metabolism. There is growing evidence that the HNS provides as a second 
neuronal-humoral system that is activated during stress (Hatton, 1990, Engelmann et al., 1998). 
Hyperactivity of the HNS may lead to a sustained somato-dendritic release of AVP into the 
extracellular fluid of both the PVN and SON (Engelmann et al., 1998). Under prolonged and repeated 
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stressor exposure, the locally high neuropeptide concentrations may partially “leak out of the 
nuclei” and reach remote limbic brain areas in neurophysiologically relevant concentrations (e.g. 
septum from the PVN or amygdala from the SON) (Engelmann et al., 2004, Landgraf, 2006). To 
differentiate between the roles of AVP signaling originating in the PVN versus SON, repeated forced 
swimming (FS) was chosen as stressful stimulus. Previous studies showed that in response to 
repeated FS, AVP is increasingly released into the extracellular fluid of PVN, but not SON (Engelmann 
et al., 1998). In more remote brain areas AVP acts as neuromodulator and neurotransmitter via local 
V1 receptors (Johnson et al., 1993, Lolait et al., 1995, Vaccari et al., 1998, Hernando et al., 2001, 
Stemmelin et al., 2005). Different lines of investigations confirmed that AVP acting in these brain 
areas regulates behavior including anxiety, social learning and memory processes (Stemmelin et al., 
2005, Engelmann, 2008).  
The literature is rich in articles describing the role of AVP in anxiety and depression (e.g. 
(Landgraf and Wigger, 2002, Scott and Dinan, 2002, Griebel et al., 2003, Keck, 2006, Landgraf, 2006, 
Frank and Landgraf, 2008, Simon et al., 2008, Surget and Belzung, 2008, Ryckmans, 2010). As both 
psychiatric disorders are considered to be stress related and AVP has a regulatory role in the HPA 
axis (Engelmann et al., 2004, Makara et al., 2004, Murgatroyd and Spengler, 2011), this connection is 
reasonable to propose. In particular, the strong connection between chronic stress and depression 
(see e.g. chronic mild stress as a model of depression (Duman, 2010, Yan et al., 2010, Overstreet, 
2012)) and the observed upregulation of AVP synthesis in parvocellular PVN neurons and V1b 
receptors at the anterior pituitary during chronic stress (Dallman, 1993, Aguilera et al., 1994) 
suggested the involvement of altered AVP signaling within the HPA axis in pathophysiological 
processes. Clinical studies found an increased AVP concentration in the cerebrospinal fluid (De Bellis 
et al., 1993, Heuser et al., 1998) and in the plasma (van Londen et al., 1997, van Londen et al., 1998, 
de Kloet et al., 2008) of depressive subjects, especially in suicide victims (Inder et al., 1997, Brunner 
et al., 2002). Postmortem studies have found an elevated number of AVP-expressing neurons, 
increased AVP level in the PVN (Purba et al., 1996, Merali et al., 2006) and an enhanced AVP mRNA 
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in the SON (Meynen et al., 2006). Additionally, a single nucleotide polymorphism of the AVP V1b 
receptor has been found to protect against major depression (van West et al., 2004). Preclinical 
studies using the first orally active non-peptide V1b antagonist (SSR 149415) resulted in a reduction 
of floating in the FS test (Griebel et al., 2002). However, a clinical study using SSR 149415 was unable 
to proof an effect on anxiety; and there was only a mild, not always reproducible, effect on 
depressive symptoms (Griebel et al., 2012). Therefore the question arose about the role central V1 
receptors may play in anxiety and depression. The fact that genetically AVP-deficient patients with 
diabetes insipidus show less anxious phenotype together with memory impairment (Bruins et al., 
2006), and that diabetes insipidus is often accompanied by memory impairment in other patients as 
well (Nabe et al., 2007), suggests the possible involvement of vasopressin signaling via peripheral V2 
receptors in behavioral processes. 
Rats of the AVP-deficient Brattleboro strain provide an interesting tool to study the role of AVP in 
neurophysiological processes. This strain was derived naturally from Long Evans rats in the early 
1960s (Sokol and Valtin, 1965, Sokol and Zimmerman, 1982). A spontaneous point mutation resulted 
in an altered AVP precursor which was unable to enter the secretory pathway (Evans et al., 2000, 
Surget and Belzung, 2008). As a result, homozygous AVP-deficient Brattleboro rats (KO) show 
diminished HPA axis responses to different acute stressors (Wiley et al., 1974, Conte-Devolx et al., 
1982, Fink et al., 1992), accompanied by reduced depressive- and anxiety-like behavioral profile 
(Mlynarik et al., 2007). More specifically, AVP-deficient rats showed higher preference for a sweet 
solution, spent considerably shorter time immobile in the FS test and less time self-grooming on the 
elevated plus maze (EPM) accompanied by a higher level of dexamethasone-induced suppression of 
corticosterone response to restraint stress. However, the lack of centrally produced AVP results in a 
variety of peripheral effects including diabetes insipidus that also affects motor behavior (Zelena et 
al., 2009). All emotional and cognitive tests in laboratory rodents measure motor behavior, and the 
outcome is interpreted in terms of emotionality and learning and memory. This bears the risk that 
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behavioral changes triggered by the physiological consequences of the absence of peripherally 
circulating AVP may be mis-interpreted as central actions of the neuropeptide.  
The goal of the present study was to investigate whether behavioral changes observed in 
Brattleboro rats are due to the lack of AVP signaling in the central nervous system versus its 
peripheral effects. As V2 receptors are expressed predominantly at the periphery e.g. in the renal 
collecting duct, we used a chronic subcutaneous treatment with a V2-receptor agonist, 
desmopressin (DDAVP; 1-deamino-8-D-arginine vasopressin) to compensate the peripheral lack of 
AVP (Robinson, 1976, Bankir, 2001, Makaryus and McFarlane, 2006). To analyse behavioral 
consequences of this treatment we used a battery of different tests primarily aimed at investigating 
emotional behavior and learning and memory that have not previously been applied in similar 
studies using Brattleboro rats and DDAVP treatment (Zelena et al., 2006, Feifel et al., 2007). Anxiety-
related behavior was studied by EPM, marble burying test (MB), defensive withdrawal (DW) and 
anhedonia was detected by sucrose preference (Misslin and Cigrand, 1986). The FS test is routinely 
used to investigate the efficacy of antidepressant treatment to modulate the behavior in lab rodents 
(Porsolt et al., 1977, Porsolt et al., 1978). For examination of recognition memory we used the object 
discrimination test (OD) (Ennaceur and Delacour, 1988, Varga et al., 2014). We hypothesized that 
the AVP deficit in KO rats would lead to attenuated anxiety- and depressive-like behavior. If this 
effect is not causally linked to the symptoms of the diabetes insipidus then DDAVP treatment should 
not significantly alter this behavioral profile. We extended our study by analyzing the impact of FS on 
c-Fos synthesis in the lateral septum and amygdala as AVP signaling in both brain areas is known to 
modulate the behavioral response during the test in an opposite manner. 
 
2. Material and Methods 
 
2. 1. Animals 
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Adult male Brattleboro rats were obtained from the local breeding colony of the Institute of 
Experimental Medicine, Budapest, Hungary. The animals were kept under controlled laboratory 
conditions with food and water ad libitum. KO animals originated from heterozygous mothers and 
KO fathers (Zelena et al., 2003). The heterozygous and KO offspring were separated based on the 
measurement of their water consumption at 5 week of age, and only the KO animals were used in 
the present study. A separate wild-type (WT) line was bred out from the Brattleboro line because 
Long Evans rats could not be used as a proper control, having already been separated for more than 
50 year (Bohus and de Wied, 1998). After mating heterozygous males and females and separating 
the homozygous KO animals from the offspring, the remaining WT or heterozygous animals were 
bred with KO males and females. For the selection of parent stocks the genotype of their offspring 
was determined by measuring their hypophyseal AVP content and those having no KO offspring 
were considered to be WT. The parents used for the WT and heterozygous line are closely related to 
each other (heterozygous mothers are the daughters of WT mothers), keeping the genetic 
background of the two lines as close as possible (Zelena et al., 2009).  
In the third examined group (DDAVP) KO rats were implanted subcutaneously with an osmotic 
minipump (Alzet osmotic minipump, 2002, 0.5μl/h/14 days) containing desmopressin (DDAVP, 
10ng/h, V2 receptor agonist, Ferring Lieciva, Czech Republic) under short ether anesthesia (~3 min 
intervention). Concomitant WT and KO animals underwent sham operation. The KO, WT and DDAVP 
groups were paired according to their age (9-12-week-old at the beginning of experimentation), 
rather than according to body weight (body weights: WT: 379.9 ± 12.1 g, KO: 265 ± 6.6 g, DDAVP: 
287.5 ± 6.5 g).   
All manipulations of the animals were approved by the local committee for animal health and care 
and performed according to the European Communities Council Directive recommendations for the 
care and use of laboratory animals (2010/63/EU). 
 
2. 2. Experiments 
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2. 2. 1. Series 1 
These experiments were performed with 30 animals (10 in each of the groups WT, KO and DDAVP). 
Within the first 24-48 h after implantation of the osmotic minipump water intake normalized (Fig. 
1A). Therefore, on day 4, after recovery, behavioral testing started. Three sessions in the defensive 
withdrawal (DW) apparatus (on day 4 morning, on day 5 morning and afternoon) were followed by 
two forced swimming (FS, one on each of day 6 and 7). On the following day (day 8) was another DW 
session combined with an airpuff as an aversive stimulus. Three days later (day 11), anhedonia was 
examined by sucrose/alcohol preference test for 24h. Finally, two days later (day 14) animals were 
tested on the elevated plus-maze (EPM). 
 
2. 2. 2. Series 2 
These experiments involved a separate group of 15 animals (five in each of the groups WT, KO and 
DDAVP). First (day 5) an OD test was conducted followed by MB two days later (day 7). One week 
later (day 13), rats were exposed to FS and two hours later deeply anesthetized and perfused for 
subsequent immunohistochemical analysis of the brain tissue (see below). 
 
2. 3. Behavioral tests 
All tests (except MB and anhedonia, for details see below) were videotaped and analyzed later by an 
experimenter blind to the treatments by means of a computer-based event recorder (H77, 
Budapest, Hungary). 
 
2. 3. 1. Defensive withdrawal 
The DW test (Takahashi et al., 1989) used a modified setup of the open field activity box. This open 
field (100 x 100 cm with 50 cm side walls) contained a dark grey PVC tube (diameter 10 × 21 cm), 
dividing the total area into two compartments: an illuminated area and a dark area. The open end of 
the tube was faced one corner at a distance of 10 cm (Engelmann et al., 1996). The box and the tube 
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were cleaned with tap water between the exposures. We analyzed the latency to leave the tube and 
the percentage of time spent in tube and in the open area (which is divided into center and 
periphery). A reduced time spent in open area and the elevation of the latency can be interpreted as 
anxiety-like behavior. 
Before the 4th session in the DW apparatus we used an airpuff for a second to the rat’s nose and 
eyes (VMD31 compressed air, Italy) (Engelmann et al., 1996). 
 
2. 3. 2. Forced swimming 
Rats were individually placed in a glass cylindrical tank (45 cm tall and 14 cm in diameter) filled with 
tap water (at 20 ± 1 °C) at a height of 30 cm. The animals were forced to swim for 10 min and then 
removed, gently dried with paper towels and returned to their home cages. We measured the 
percentage of time spent by the animal in a typical immobile posture (floating) during the swimming 
session (rated as depression-like behavior). Floating was defined as immobility of the animal with 
movements that keep its head above the water only (Porsolt et al., 1977). Climbing/struggling was 
defined as vigorous movements of the four limbs, with the fore paws breaking through the water’s 
surface, along the wall of the tank (Wongwitdecha et al., 2006). Swimming differs from climbing that 
the rats make coordinated and sustained movements with all four limbs, usually traveling around 
the interior of the cylinder, but did not break the surface of the water (Bravo and Maswood, 2006). 
During diving the rats submerged entire head and body beneath the water surface (Arunrut et al., 
2009, Pinter et al., 2011). 
 
2. 3. 3. Anhedonia 
Sucrose preference, alcohol preference, and total fluid consumption were measured using a two-
bottle, free-choice test over a single 24 h period in the home cage (Fodor et al., 2012). One bottle 
contained 2.5% sucrose in water, whereas the other bottle contained 8% ethanol (ETOH) in a 2.5% 
sucrose-water solution.  
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2. 3. 4. Elevated plus maze 
The EPM apparatus was made of metal and painted dark grey (elevated 70 cm above the floor, arm 
length: 50 cm; arm width: 15 cm; central platform: 15 × 15 cm; closed arm walls height: 40 cm). Each 
rat was transferred in the homecage from the housing room to the brightly lit (~ 50 Lux) test room. 
Immediately after arrival in the test room, the animal was placed on the central arena of the 
elevated plus maze, with the head facing a closed arm. EPM exposure lasted 5 min. The percentage 
of time spent in open arms and open/total (open plus closed) arm entries ratio (an entry was 
defined as having three paws of animal in a defined compartment) were calculated and used as 
measures of anxiety-like behavior. The number of closed arm entries was used to estimate the 
general locomotor activity of the animal. 
 
2. 3. 5. Marble burying 
The MB test was performed as a modified version (Li et al., 2006) of the test originally described for 
testing mice (Broekkamp et al., 1986, Njung'e and Handley, 1991, Borsini et al., 2002, Nicolas et al., 
2006, Egashira et al., 2007). The rats were placed individually in a plexiglass cage (41.3cm x 26 cm x 
29.8 cm high, Ferplast, Geo Maxi, Italy) with a 5 cm deep layer of bedding holding 15 marbles on its 
surface (25 mm diameter; arranged in a 3 x 5 pattern; space between two marbles ~ 4.5 cm). A 
session in the MB test lasted 30 min. A trained observer counted and noted every fifth minute the 
number of buried and half-buried marbles. 
 
2. 3. 6. Object discrimination 
One hour before the test rats were put into a plexiglass box (Ferplast, Geo Maxi, Italy) with food and 
water ad libitum to freely explore the new environment. Then one of two objects (i.e. glass jar: 6.5 
cm diameter, 8.5 cm length and metal jar: 9.5 cm diameter, 4 cm length) was introduced in one of 
the corners of the box. The rat was allowed to explore this object (subsequently called ’familiar’) for 
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4 min; then the object was removed. After 30 min, the ’familiar’ object was placed together with the 
other (subsequently called ’non-familiar’) object into the box for another 4 minutes. The objects and 
their location in the box (left – right) were randomized to avoid place preference. The discrimination 
index (DI) was calculated from the time spent exploring/sniffing the objects: DI = (investigation 
duration non-familiar - investigation duration familiar)/(investigation duration non-familiar + 
investigation duration familiar) (Varga et al., 2014). 
 
2. 4. Immunohistochemistry 
Two hours after a single 10 min FS animals were anaesthetized with a ketamin-xylazin-pipolphen 
cocktail (50-10-5 mg/kg in 2ml/kg, intraperitoneal) and intracardially perfused with saline followed 
by 300 ml of 4 % paraformaldehyde (0 °C). The brains were removed and post-fixed in the same 
solution at 4 °C overnight. On the following day brains were washed with phosphate-buffered saline 
(PBS: 1.56 g NaH2PO4, 30.8 g NaHPO4×12H2O, 5 g NaCl and 0.2 g MgCl in 1 l distilled water) and 
transferred into 20 % sucrose in PBS. After two days brains were removed from PBS, shock-frozen (-
70 °C), packed in aluminium foil, and kept at -80°C until sectioning. Frozen sections (30 μm) were cut 
in coronal plane on a sliding microtome and were put into antifreeze liquid at -20 °C. 
The brain sections were processed for c-Fos immunoreactivity. Before the immunoreaction brain 
sections were washed 3 x 10 min with PBS, followed by 0.2 % Triton-X-100 and H2O2 solutions to 
inactivate the endogenous peroxidase. After that sections were washed again with PBS for 3 x 5 min, 
then incubated in 2 % normal Horse Serum for 20 min to block non-specific proteins activity, which 
followed by a new PBS washing for 3 x 10 min. Sections were incubated overnight in polyclonal 
rabbit primer antibody (Santa Cruz Biotechnology, USA, sc-52; 1:5000 dilution, 4C) followed by PBS 
washing for 3 x 10 min. The sections were then rinsed and exposed to an anti-rabbit secondary 
antibody (Jackson Immunoresearch Laboratories, 1:1000) for one hour, then washed with PBS for 2 x 
10 min. An avidin-biotin complex (Vectastain ABC kit, 1:1000) peroxidase procedure with nickel-
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diaminobenzidine as the chromogen was used to visualize the immunoreactivity. The sections were 
covered with DePeX. 
Quantification of the c-Fos immunoreactivity was done in defined septal and amygdaloid nuclei. 
Section planes were standardized according to the atlas of Paxinos and Watson (Paxinos and 
Watson, 1998) by an experimenter blind to the treatment groups using sections matching the same 
coordinates of the brain atlas for each animal. Microscopic images were digitized by an OLYMPUS 
BX51 camera using a magnification 10 x. The average of four sections taken at 80 μm intervals was 
used for the analysis of each structure, including both hemispheres; that is, eight measures per area 
and animal. To select c-Fos immunopositive nuclei as targets for quantification, a PC-based software 
(Image J, http://rsbweb.nih.gov/ij/) was used and targets were subsequently identified in the 
captured images by gray level thresholding. For each brain area, the threshold for the labeled signal 
was defined according to the background staining. Size criteria were applied to exclude structures 
other than c-Fos immunopositive nuclei from measurement, therefore only particles with a 
minimum area of 20 pixels were considered as a cell nucleus. The number of c-Fos positive nuclei 
was calculated as the average number obtained of all analyzed images per one rat. 
 
2. 5. Statistical analysis 
Data were analyzed by analysis of variance (ANOVA) using the ANOVA/MANOVA module of the 
STATISTICA 11.0 software package (Tulsa, OK, USA). One (factor ‘group’: WT, KO, DDAVP) or two way 
ANOVA (factors ‘group’ and ‘time’; with repeated measures on the second factor) were applied. In 
case the main effect of ANOVA was significant multiple pairwise comparisons were made by the 
Newman-Keuls method. The difference of the discrimination index from 0 (no discrimination value) 
was tested with one sample t test. Pearson correlations were calculated by multiple linear regression 
analysis. Data are expressed as mean ± SEM and the level of significance was set at p < 0.05. 
 
3. Results 
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3. 1. Physiological parameters 
The higher water consumption of KO versus the WT animals remained significant throughout (factor 
’group’: p < 0.001). Within 24-48 h after implantation of the minipumps water intake reached the 
level of the WT animals in DDAVP treated rats, illustrating the successful treatment of the peripheral 
symptoms of the diabetes insipidus (Fig. 1A; both factor ’time’ and ’group’ x ‘time’ interaction: p < 
0.001). 
The body mass increased in the animals of all groups during the course of the experiment (factors 
‘group’, ‘time’ and ‘group’ x ‘time’ interaction: p < 0.001). Initially, the body mass of the KO rats was 
~ 30% lower than that of WT animals (first measurement, factor ’group’: p < 0.001). Although in 
DDAVP treated animals the body mass increased significantly after onset of the treatment (last 
measurement, factor ’group’: p < 0.001), it did not reach the level of the WT group until the end of 
the study (Fig. 1B). 
We also measured the mass of the adrenal glands, to obtain a parameter allowing some insight into 
the glucocorticoid supply. The absolute adrenal mass was significantly lower in KO than in WT 
animals (factor ‘group’: p < 0.001). However, if referenced to the body mass (calculated as relative 
organ mass) the difference between the groups disappeared (data not shown). 
3. 2. Behavioral parameters 
3. 2. 1. DW test 
Figure 2 shows the results obtained in the DW test. The first three sessions were used to habituate 
the animals to the DW apparatus. After habituation the animals swam twice for 10 min. The latter 
was done to trigger the release of AVP into the extracellular fluid of the PVN (Engelmann et al., 
1998). Airpuff startle applied before the fourth DW session was previously reported to increase 
anxiety (Engelmann et al., 1996) and thought to enhance the differences between the treatment 
groups. Statistical analysis revealed that during the successive sessions the animals spent an 
increasing duration in the tube, and the latency to enter the periphery was increased (factor ‘time’: 
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p<0.001; Fig. 2A). WT animals showed significantly increased latency to leave the tube compared to 
the other groups (factor ‘group’: p < 0.01). Specifically, the latency to leave the tube failed to differ 
between the DDAVP treated and KO rats during the sessions 1-3. After forced swimming and airpuff-
startle, during session 4, the latency of leaving the tube in the DDAVP group did not differ 
significantly both from KO and WT animals (Fig. 2A).  
Another parameter extracted from the behavioral profile of the animals in the DW apparatus 
(quotient of the time rats spent in center/open field) reached nearly zero in WT animals during 
sessions 2-4 (factor ‘session’: p < 0.001; Fig. 2B). In contrast, throughout these sessions DDAVP 
treated rats spend significantly more time in the center (factor ‘group’: p = 0.01). Also, KO animals 
tended to spent more time in the center (p = 0.09). 
 
3. 2. 2. FS test 
Statistical analysis revealed a significant difference between WT and KO rats during both the  two FS 
sessions in Experiment 1 and the session in Experiment 2 (Fig. 3; data are shown from session 2 of 
Exp. 1 and Fig.6C; Exp. 2) in the percentage of time spent floating (factor ‘group’: p < 0.05; Fig. 3A; 
Fig.6C). Subsequent analysis revealed that both DDAVP treated and KO rats spend significantly less 
time floating than WT animals. The time spend in active behavior was also significantly different 
between the groups, however, during Experiment 1 only struggling (factor ‘group’: first: p = 0.002; 
second: p = 0.001; Fig. 3B), whereas during Experiment 2 only swimming (factor ‘group’: p < 0.05; 
Fig. 6C) were detected to differ statistically significantly. 
Interestingly, the number of faeces boli found at the end of the 10 min swimming session paralleled 
the floating behavior (Fig. 3C, D). Namely this parameter was significantly lower in KO vs. WT 
animals (factor ‘group’: p < 0.05); but DDAVP failed to significantly alter the number of faeces boli 
when compared to KO animals. There was a positive correlation between the time spent floating and 
the number of faeces boli both during the first (p=0.02; r=0.417) and also during the second session 
(p=0.018; r=0.427). 
You created this PDF from an application that is not licensed to print to novaPDF printer (http://www.novapdf.com)




3. 2. 3. Anhedonia test 
In contrast to previous reports (Mlynarik et al., 2007) we were unable to find an enhanced sucrose 
preference in KO animals (Supplementary Fig. 1). 
 
3. 2. 4. EPM test 
Statistical analysis revealed that the percentage of time spent on the open arms differed significantly 
between the groups tested (factor ‘group’: p < 0.01; Fig. 4A). Post hoc analysis showed that WT rats 
spent significantly less time on the open arm than KO or DDAVP treated groups; the two later groups 
did not differ in their reduced anxiety-like behavior. The other main parameter, the open arm 
frequency (percentage of open and close arm frequency as a locomotion independent measure) 
represented also a significant difference between groups (factor ‘group’: p = 0.02; Fig. 4B). During 
the post hoc comparison the WT animals entered less to the open arm (lower frequency) than 
untreated or DDAVP treated KO rats. Locomotion, estimated upon the closed arm frequency, did not 
differ between the groups (Fig. 4C).  
 
3. 2. 5. Marble burying test 
There was a significant difference between the three groups (factor ‘group’: p = 0.012) during the 
marble burying test, and the number of buried marbles depended upon the time (factor ‘time’: p < 
0.01; Fig. 4D). During the test the WT animals buried an increasing number of marbles, whereas KO 
and DDAVP rats buried 1-2 marbles only. 
 
3. 2. 6. Object discrimination test 
During the sampling session all rats spent enough time investigating the to-be-recognized object to 
become familiar with it (Fig. 5A), showing no significant difference in the investigation duration 
between the different groups. As indicated by the significantly longer investigation duration of the 
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novel object during the discrimination session WT animals showed intact discrimination abilities, 
while the DDAVP group failed to do so (single sample t test; Fig. 5B). There was a tendency for higher 
‘discrimination index’ of WT animals compared to KO or DDAVP treated rats that just failed to reach 
statistical significance (factor ‘group’: p = 0.05).   
 
3. 2. 7. c-Fos immunohistochemistry 
After forced swim test we measured c-Fos immunohistochemistry in three distinct parts of both the 
lateral septum (dorsal: LSD, intermediate: LSI, ventral part: LSV) (Fig. 6A) and the amygdala (medial: 
MeA, central: CeA, basolateral amygdala: BLA) (Fig. 6B). The number of labeled cells was similar in all 
three groups in the different parts of the lateral septum (the highest number of labeled cells found 
in LSV). However, the number of labeled cells was found to be significantly different in MeA between 
WT and both KO and DDAVP groups (factor ‘group’: p=0.015). Further, we found a significant 
correlation between the number of c-Fos labeled cells in MeA and both the time spent floating 
(p=0.003; r=-0.77) and the time spend swimming (p=0.0074; r=-0.75) (Fig. 6C). The correlation 
analysis of the other two parts of the amygdala showed a similar tendency, but it failed to reach the 
level of statistical significance. 
 
4. Discussion 
Our data confirm that DDAVP treatment compensated for the peripheral effects of AVP-
deficiency and thereby eliminated the symptoms of the diabetes insipidus, indicated by the 
normalized water consumption and the increased body weight gain in DDAVP animals. As 
subsequently KO and DDAVP treated animals showed a different body weight but failed to differ in 
their behavioral profile it is unlikely that original differences seen between WT and KO animals can 
be simply related to body weight differences. Thus, our present results confirm previous findings 
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suggesting an anxiolytic-like and a reduced depressive-like behavioral profile of KO rats (Mlynarik et 
al., 2007).  
One of the most widely used tests for anxiety in laboratory rodents is the EPM. It was used 
to selectively bread high (HAB) and low anxiety (LAB) rat and mouse lines which were reported to 
show alterations in the AVP signaling that is probably responsible for high anxiety phenotype in HAB 
animals (Landgraf and Wigger, 2003, Murgatroyd et al., 2004, Kessler et al., 2007, Landgraf et al., 
2007). Our results are in accordance with these studies as we found that the congenital absence of 
AVP in the brain is accompanied by lower anxiety-like behavioral profile, similarly to LAB animals. In 
a previous study on Brattleboro animals (Mlynarik et al., 2007) we did not find this difference, but in 
those experiments heterozygous animals were used as controls, while in the present study WT- 
animals were used. Nevertheless, the DW, which also tests innate fear from open spaces 
(Engelmann et al., 1996), showed also similar results, thereby confirming the results on the EPM in 
the present study. Another facet of innate fear, aimed at testing the aversive impact of novel 
objects, was studied by the MB test. Again we observed a significant difference between KO and 
DDAVP versus WT Brattleboro rats with the latter burying significantly more marbles. Taken 
together, our data suggest that the behavioral changes observed in three different tests 
investigating distinct facets of innate fear cannot be corrected by treating the peripheral symptoms 
of diabetes insipidus and are, thus, primarily linked to the action of central AVP signaling. However, 
we cannot entirely exclude that the developmental effects of AVP-deficiency (Hammock, 2014) 
contribute to behavioral alterations which cannot be restored by acute/subacute treatment in 
adulthood. In this context it seems worth noting that different other systemic treatments (e.g. with 
antipsychotic drugs) were able to “normalize” distinct behavioral parameters in Brattleboro rats 
(Feifel et al., 2009, Cilia et al., 2010). 
A widely used test for antidepressant development is FS. Here we could repeatedly confirm 
more active behavioral response in AVP-deficient Brattleboro rats. This is in line with the assumption 
that central AVP signaling may play an important role in the development of depressive pathology 
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(Landgraf and Wigger, 2002, Scott and Dinan, 2002, Griebel et al., 2003, Keck, 2006, Landgraf, 2006, 
Frank and Landgraf, 2008, Simon et al., 2008, Surget and Belzung, 2008, Ryckmans, 2010). Infusion of 
V1a and V1b antagonists not only into systemic circulation (Overstreet and Griebel, 2005) but also 
into the PVN (Wigger et al., 2004), septum (Stemmelin et al., 2005) and the amygdala (Ebner et al., 
2002) increased the active behavior during FS. Previous studies showed that in response to repeated 
FS AVP is released not only from the axon terminals into the blood stream, but also from the somata 
and dendrites of vasopressinergic neurons into the extracellular fluid of the PVN (Engelmann et al., 
1998, Ebner et al., 2002, Engelmann et al., 2004, Wigger et al., 2004). As antisense mRNA of AVP into 
the septum decreased the anxiety-like behavior in rats, this brain region seemed to be the most 
important target of somatic-dendritic AVP release (Landgraf et al., 1995).  
 A particularly interesting finding of the present study concerns the observation of a 
significant correlation between the percentage of time spend floating and the increased number of 
c-Fos positive cells in the MeA (Fig. 6). Previously it was shown that FS triggers AVP release within 
the amygdala complex and V1 receptor antagonist treatment significantly reduces floating and 
increased struggling behavior in male rats (Ebner et al., 2002). Due to technical limitations of the 
microdialysis technique, a more specific analysis which of the parts of the amygdala complex might 
have played a particular role in the observed effects was impossible. The present study confirms not 
only that blocked/absent AVP-signaling within this brain area causes a more active behavioral 
response during forced swimming, they also extend the previous findings by suggesting that the 
MeA and, perhaps to a lesser extent the CeA and BLA, plays an important role in the behavioral 
regulation during defined stressor exposure. Different studies suggested an involvement of 
amygdaloid V1b receptor in FS behavior (Salome et al., 2006) and V1a receptors in the amygdala, but 
not in the lateral septum, modulated the behavior in a paradigm for female anxiety (Poirier et al., 
2013). In this context it is of note that V1a (Bielsky et al., 2004) and V1b (Egashira et al., 2005) 
receptor deficient mice failed to show a behavioral difference to WT animals in the FS test. These 
data suggest a species-specific effect of local AVP signaling. 
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Interestingly, the number of c-Fos positive cells was not significantly altered in the areas 
constituting the lateral septum of KO and DDAVP treated rats when compared with WT animals (Fig. 
6). This sheds new light on data of two other studies reporting a significant impact of V1 receptor 
antagonist treatment in the lateral septum (Ebner et al., 1999) versus the MeA (Ebner et al., 2002) 
on FS behavior of adult male rats. Interestingly, in the septum the treatment effects were exactly the 
opposite than those observed in the MeA. Therefore, it was concluded that AVP controls the 
behavioral response in both brain areas that results in a balanced response during FS (Ebner et al., 
2002). Upon first glance, the present findings could not only suggest that the MeA plays an 
important role in the control of FS behavior, but also that the congenital absence of AVP signaling at 
brain level does not result in a balanced behavioral response. However, a closer look reveals that the 
behavioral data obtained during FS do not show without doubt that the lack of AVP signaling in the 
amygdala ‘overrules’ the absence in the lateral septum. As a consequence, further studies have to 
analyze whether the behavioral profile is indeed primarily controlled by the ‘septum versus MeA 
balance’ or the result of a downstream manifestation of altered, behaviorally relevant AVP signaling 
elsewhere in the brain. Therefore, it would be worth testing whether during acute stressor exposure 
somatic-dendritic release of AVP from the SON versus PVN might influence the behavioral response 
in addition to local signaling (Ebner et al., 2002, Ludwig and Leng, 2006).  
Anhedonia was suggested to be one of the core symptoms of depression (Di Giannantonio 
and Martinotti, 2012, Harden et al., 2012, Hill et al., 2012, Warnock et al., 2012). Our experiment 
investigating anhedonia in KO rats failed to reveal significant differences between the groups. This 
observation, however, may be hampered by the physiologically disturbed fluid consumption in KO 
animals and, therefore, does not provide an unbiased outcome.  
Taking into consideration the high prevalence of cognitive disturbances in depression 
(Murrough et al., 2011) we also studied this aspect of our rats. The short term memory and learning 
processes were examined by object discrimination, as we did not wanted to confound our results 
with potential social alterations (Neumann and Landgraf, 2012). We confirmed the positive effect of 
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centrally released AVP in short-term recognition memory. Previous studies used social discrimination 
tests in Brattleboro rats and showed that AVP injection to the septum improved their social 
discrimination skills (Dantzer and Bluthe, 1993, Engelmann and Landgraf, 1994, Landgraf et al., 
1995). Thus, our data extend the findings using conspecifics as stimuli and show that the absence of 
central AVP signaling results in an impaired short-term recognition memory also towards objects. 
 
5. Conclusions 
In summary, male AVP-deficient Brattleboro rats showed in several tests (DW, FS, EPM, MB) 
a behavioral profile that can be interpreted as reduced anxiety and/or depressive-like which was not 
„normalized” after peripheral replacement of AVP by chronic DDAVP treatment acting via V2 
receptors. In addition, KO animals showed – similar to previously reports – short-term recognition 
memory deficits. As the DDAVP treated animals behaved similarly to untreated KO rats in all studied 
tests, it is quite probable that the effect of AVP on affective and memory symptoms is due to its 
central (neuromodulator/neurotransmitter via V1a and V1b receptors) rather than peripheral role 
(antidiuretic hormone via V2 receptors). Further studies have to reveal whether indeed the MeA, 
rather than the lateral septum contributes primarily to the behavioral effects of intracerebrally 
signaling AVP, e.g. after its release from the somata-dendrites during defined stressor exposure. 
 
You created this PDF from an application that is not licensed to print to novaPDF printer (http://www.novapdf.com)






Figure 1: Effects of DDAVP treatment on distinct physiological parameter 
(A) After the osmotic minipump implantation KO rats’ (day 0) water consumption normalized within 
1-2 days, thus the compensation of the peripheral lack of AVP was successful. (B) Body mass 
increased in all groups, and DDAVP treated group gain significantly more mass than KO rats. Y axis 
reflects the days after minipump implantation. Data from experimental series 1; n = 10 for each 
group; WT: wild type, KO: homozygous vasopressin-deficient rat; DDAVP: desmopressin treated KO 




Figure 2: Effects of DDAVP treatment on behavioral parameters measured in the defensive 
withdrawal test combined with forced swim test and airpuff 
(A) During the experiment the latency to enter the periphery increased after the first session then 
during the second and third test animals were habituated to this environment, and in these sessions 
latency did not change. After forced swim and airpuff the WT group stayed longer in the safe 
compartment than the other groups. (B) In the fourth session –after FS and airpuff exposure – WT 
rats spent significantly less time in the center of the DW apparatus compared to KO and DDAVP 
animals. Data from experimental series 1; n = 10 for each group; WT: wild type, KO: homozygous 
vasopressin-deficient rat; DDAVP: desmopressin treated KO rats; FS: forced swim test for 10 min; 
*p<0.05 **p<0.01: KO and DDAVP vs. WT main group effect; ++p<0.01 vs. first session 
 
 
Figure 3: Effects of DDAVP treatment on the behavior in the forced swim test 
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This Figure shows exemplarily the behavioral profile obtained during the second FS session. (A) WT 
rats showed significantly more floating (depressive-like behavior) than DDAVP treated and untreated 
KO rats. (B) Struggling revealed also a significant difference between groups. (C) The number of boli 
in the water differed significantly between WT and KO/DDAVP-treated rats. (D) Regression analysis 
of the floating time and the number of faeces boli during the second session (raw data are on part A 
and C). Data from experimental series 1; n = 10 for each group; WT: wild type, KO: homozygous 
vasopressin-deficient rat; DDAVP: desmopressin treated KO rats; FS: forced swim test for 10 min; 
*p<0.05 **p<0.01: KO and DDAVP vs. WT 
 
 
Figure 4: Effects of DDAVP treatment on anxiety-like behavioral responses in elevated plus maze 
(A-C) and marble burying test (D) 
(A) Percentage spent on open arm, (B) percentage of entries into the open arms and (C) absolute 
number of entries into the closed arms of the EPM. (D) Number of marbles buried. A-C: Data from 
experimental series 1; n = 10 for each group; D: Data from experimental series 2; n = 5 for each 
group; WT: wild type, KO: homozygous vasopressin-deficient rat; DDAVP: desmopressin treated KO 
rats; *p<0.05; **p<0.01 KO and DDAVP vs. WT; +p<0.05 KO and DDAVP vs. WT main group effect 
 
 
Figure 5: Effects of DDAVP treatment on short-term object discrimination 
(A) All groups spent a similar duration investigating the to-be-recognized object during sampling. (B) 
Based on discrimination index (see Material & Methods) WT animals showed significantly better 
discrimination abilities than AVP deficient rats during choice. Data from experimental series 2; n = 5 
for each group; WT: wild type, KO: homozygous vasopressin-deficient rat; DDAVP: desmopressin 
treated KO rats; *p<0.05 KO vs. WT  
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Figure 6: Effects of DDAVP treatment on the stressor exposure induced c-FOS synthesis in septum 
and amygdala 
Number of positively c-Fos-stained cells in distinct nuclei of (A) the septum and (B) amygdala. (C) 
Regression analysis of the number of c-Fos labeled cells in the MeA and floating duration 
during FS (see inset for the raw behavioral data). Data from experimental series 2; n = 5 for each 
group; WT: wild type, KO: homozygous vasopressin-deficient rat; DDAVP: desmopressin treated KO 
rats; LSD: lateral septum dorsal part, LSI: lateral septum intermediate part, LSV: lateral septum 
ventral part, MeA: medial amygdala, CeA: central amygdala, BLA: basolateral amygdala; *p<0.05 KO 
and DDAVP vs. WT  
 
 
Supplementary Figure 1: Effects of DDAVP treatment on sucrose preference 
Percentage of consumed sucrose relative to total fluid intake. Data are from experimental series 1; n 
= 10 for each group; WT: wild type, KO: homozygous vasopressin-deficient rat; DDAVP: 
desmopressin treated KO rats; # p < 0.05 DDAVP vs. KO 
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